DOSE OF REALITY: NEW STUDY DEBUNKS BIG PHARMA CLAIMS THAT HIGH PRESCRIPTION DRUG PRICES ARE TIED TO R&D INVESTMENTS
JAMA Network Open Paper Finds “No Relationship” Between Drug Company’s… Read More

JAMA Network Open Paper Finds “No Relationship” Between Drug Company’s… Read More
Shining a Light on How Big Pharma is Rapidly Increasing Prices on Oncology… Read More
Analysis Highlights How Escalating Prescription Drug Costs, Driven By Big… Read More
Lawmakers Can Highlight Tactics Designed to Block More Affordable Alternatives… Read More
FTC Workshop Can Highlight How Brand Name Drug Companies Employ… Read More
Lawmakers Should Focus Attention on Brand Name Drug Companies’ Egregious… Read More
Academic Study Underscores How Big Pharma’s Price-Gouging on Treatments for… Read More
Congress Can Refocus Attention on Market-Based Solutions to Crack Down on… Read More
Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for… Read More
Part I: Price-Gouging An Unproven Treatment, Setting Out-of-Control Launch… Read More
Part II: Pushing Debunked Innovation Rhetoric to Oppose Rx Solutions Despite… Read More
Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual… Read More